Knoll Capital Management, LLC
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 18, 2025), Knoll Capital Management, LLC reported 35 stock positions worth $155.3 million. Its top holding was Biohaven Pharmaceutical Hold at 18.3% of the portfolio, followed by Aldeyra Therapeutics (ALDX, 17.6%) and Entera Bio (ENTX, 8.0%). Compared with Q3 2024, it sold out of 1, added to 3 and reduced 3. The biggest buy was Entera Bio (ENTX, shares +52%) and the biggest sale Hookipa Pharma (shares −10%).
- Most Recent 13F
- Q2 2026
- Location
- MIAMI, FL
- CIK
- 0001325083
- Portfolio Value
- $155.3M (Q4 2024)
- SEC Filing
- 0001104659-25-014391 ↗ filed Feb 18, 2025
Holdings Value
Holdings 35 stocks · $155.3M
| BIOHAVEN PHARMACEUTICAL HOLD | 18.28% | 760,422 | $28.4M | Add +7.0% |
| ALDX Aldeyra Therapeutics Inc. | 17.59% | 5,475,516 | $27.3M | No change |
| ENTX Entera Bio Ltd. | 8.03% | 5,881,879 | $12.5M | Add +51.5% |
| VRNA Verona Pharma Ltd. | 5.98% | 200,000 | $9.3M | No change |
| ALT Altimmune Inc. | 5.21% | 1,121,524 | $8.1M | No change |
| GLD SPDR Gold Shares | 4.99% | 32,000 | $7.7M | No change |
| MGTX Meiragtx Holdings PLC | 4.90% | 1,250,000 | $7.6M | No change |
| AVDL Avadel Pharmaceuticals plc | 4.06% | 600,000 | $6.3M | No change |
| OCUL Ocular Therapeutix Inc. | 3.30% | 600,400 | $5.1M | No change |
| APLT Applied Therapeutics Inc. | 3.20% | 5,799,687 | $5.0M | Add +4.0% |
| AEM Agnico Eagle Mines Ltd. | 2.79% | 55,500 | $4.3M | No change |
| KGC Kinross Gold Corp. | 2.63% | 440,000 | $4.1M | No change |
| SA Seabridge Gold Inc. | 2.33% | 317,003 | $3.6M | No change |
| FNV Franco-Nevada Corp. | 1.89% | 25,000 | $2.9M | No change |
| EQX Equinox Gold Corp. | 1.78% | 550,811 | $2.8M | No change |
| SKE Skeena Resources Ltd. | 1.77% | 315,400 | $2.8M | No change |
| MAG Mag Silver Corp. | 1.49% | 170,000 | $2.3M | No change |
| SLV iShares Silver Trust | 1.36% | 80,000 | $2.1M | No change |
| BAH Booz Allen Hamilton Holdings | 1.08% | 13,000 | $1.7M | No change |
| V Visa Inc. Class A | 0.99% | 4,850 | $1.5M | No change |
| PM Philip Morris International | 0.77% | 10,000 | $1.2M | No change |
| ITA iShares U.S. Aerospace & Def | 0.72% | 7,650 | $1.1M | No change |
| NOC Northrop Grumman Corp. | 0.65% | 2,165 | $1.0M | No change |
| HOOKIPA PHARMA INC | 0.65% | 498,625 | $1.0M | Reduce -9.6% |
| RGLD Royal Gold Inc. | 0.64% | 7,550 | $995K | No change |
| MREO Mereo Biopharma Group PL-ADR | 0.59% | 260,470 | $912K | No change |
| DEO Diageo PLC-Sponsored ADR | 0.55% | 6,750 | $858K | No change |
| AGI Alamos Gold Inc. Class A | 0.49% | 41,000 | $756K | No change |
| WPM Wheaton Precious Metals Corp. | 0.45% | 12,500 | $703K | No change |
| NEWP New Pacific Metals Corp. | 0.37% | 485,000 | $572K | No change |
| SILV Silvercrest Metals Inc. | 0.35% | 60,000 | $546K | No change |
| CRDL Cardiol Therapeutics Inc. Class A | 0.08% | 100,000 | $128K | No change |
| Orgenesis, Inc. | 0.06% | 50,623 | $96K | Reduce -20.2% |
| GRAL Grail Inc. | 0.00% | 100 | $2K | No change |
| IRD Opus Genetics Inc. | 0.00% | 45 | $53 | Reduce -100.0% |
Portfolio Sells Q3 2024 → Q4 2024
| HOOKIPA PHARMA INC | Reduce -9.6% | 0.65% | −2.69 |
| CVS CVS Health Corp. | Sold out | 0.00% | −0.42 |
| Orgenesis, Inc. | Reduce -20.2% | 0.06% | −0.07 |
| IRD Opus Genetics Inc. | Reduce -100.0% | 0.00% | −0.06 |
Portfolio Buys Q3 2024 → Q4 2024
| ENTX Entera Bio Ltd. | Add +51.5% | 8.03% | +4.61 |
| BIOHAVEN PHARMACEUTICAL HOLD | Add +7.0% | 18.28% | +1.83 |
| APLT Applied Therapeutics Inc. | Add +4.0% | 3.20% | −18.76 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026Amended | 37 | $214.3M | BIOHAVEN PHARMACEUTICAL HOLD, MGTX, PHYS, ALDX, OCUL |
| Q1 2026 | 37 | $188.7M | BIOHAVEN PHARMACEUTICAL HOLD, PHYS, RGLD, MGTX, AEM |
| Q4 2025 | 33 | $218.0M | ALDX, BIOHAVEN PHARMACEUTICAL HOLD, NUVB, AVDL, GLD |
| Q3 2025 | 38 | $186.6M | ALDX, BIOHAVEN PHARMACEUTICAL HOLD, GLD, ENTX, MGTX |
| Q2 2025 | 38 | $140.7M | ALDX, BIOHAVEN PHARMACEUTICAL HOLD, ENTX, GLD, MGTX |
| Q1 2025 | 36 | $153.7M | ALDX, BIOHAVEN PHARMACEUTICAL HOLD, ENTX, GLD, MGTX |
| Q4 2024 | 35 | $155.3M | BIOHAVEN PHARMACEUTICAL HOLD, ALDX, ENTX, VRNA, ALT |
| Q3 2024 | 36 | $215.8M | APLT, BIOHAVEN PHARMACEUTICAL HOLD, ALDX, AGI, AVDL |
| Q2 2024 | 35 | $148.4M | APLT, BIOHAVEN PHARMACEUTICAL HOLD, ALDX, AVDL, ALT |
| Q1 2024 | 34 | $160.7M | APLT, BIOHAVEN PHARMACEUTICAL HOLD, ALDX, AVDL, GLD |